Multispan and Promega streamlining GPCR screening

Promega and San Francisco area-based Multispan have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening by combining Multispan GPCR cell lines and Promega bioluminescent technologies.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MADISON, Wis.—Promega and San Francisco area-based Multispan have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening by combining Multispan GPCR cell lines and Promega bioluminescent technologies. The first tools will support cell lines and cAMP-Glo Assay for quantification of signal. Additional tools will be developed for cell-based assay detection. This combination of validated biologic components and a sensitive and dynamic luminescence assay detection technology for high-throughput screening reportedly will provide increased speed and efficiency in GPCR drug screening."Pre-optimized protocols will reduce assay development times, from months to days, helping deliver better GPCR targeted drugs faster," according to John Watson, marketing director of pharma/biotech at Promega. "Our suite of assay tools can be combined with Multispan's validated GPCR cell lines to provide turnkey solutions for drug discovery scientists."

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue